Three Months Ended

Nine Months Ended

March 31,

2023

2022

2023

2022

Basic and diluted numerator:

Net loss attributable to iBio, Inc. from continuing operations

$

(6,279)

$

(6,746)

$

(24,379)

$

(19,125)

Preferred stock dividends – iBio CMO Preferred Tracking Stock

—

(88)

Net loss available to iBio, Inc. stockholders from continuing operations

$

(6,279)

$

(6,746)

$

(24,379)

$

(19,213)

Net loss available to iBio, Inc. stockholders from discontinued operations

$

(1,015)

$

(5,644)

$

(34,598)

$

(14,124)

Net loss available to iBio, Inc. stockholders - total

$

(7,294)

$

(12,390)

$

(58,977)

$

(33,337)

Basic and diluted denominator:

Weighted-average common shares outstanding

13,184

8,719

10,592

8,719

Per share amount - continuing operations

$

(0.47)

$

(0.77)

$

(2.30)

$

(2.20)

Per share amount - discontinued operations

$

(0.08)

$

(0.65)

$

(3.27)

$

(1.62)

Per share amount - total

$

(0.55)

$

(1.42)

$

(5.57)

$

(3.82)